A novel disinfectant platform using peroxyacid compounds (peracetic and performic acid) that achieve rapid germ-kill at high dilutions (1:200) across diverse organisms. Nontoxic additives like chitosans and surfactants create lasting bacteriostatic surface coatings, enabling effective water and surface disinfection with minimal chemical use.
This research program develops optimized peroxyacid-based disinfectant formulations capable of achieving greater than 3-log inactivation of bacteria, viruses, spores, and fungi within 10 minutes at dilutions as high as 1:200. The technology targets both aqueous disinfection (water and wastewater) and surface applications (hard surfaces and fabrics). A key innovation is the incorporation of nontoxic additives such as chitosans and surfactants that form persistent bacteriostatic coatings on treated surfaces without reducing the germ-kill performance of the active peroxyacid compounds. This dual-action approach delivers rapid disinfection while providing residual surface protection, addressing a critical gap in conventional disinfectants that lose efficacy once dry.
Core active ingredients:
Performance targets:
Additive system:
Regulatory status: Peroxyacids already hold regulatory approval for many disinfection applications, supporting a streamlined commercialization pathway.
The technology is currently at proof-of-concept stage (TRL 3–4). Prior bench-scale screening and time-resolved batch disinfection trials over a two-year period have demonstrated promising inactivation performance at dilutions from 1:100 to 1:1000 in water, wastewater, and hard surface applications. A planned six-month proof-of-concept study will conduct high-throughput screening followed by batch experiments testing multiple dilutions (1:100, 1:300, 1:1000) against a panel of indicator organisms at 25 °C, with survival analysis at 1, 3, 10, and 30 minutes using standard culture methods. Further validation is needed to confirm additive coating persistence and performance under real-world conditions.
UNC–Chapel Hill is a comprehensive public research university and the state’s flagship, pairing broad academic depth with a major academic health system. Industry partners access co‑located core facilities, sponsored research, and an on‑campus innovation hub that connects companies to faculty and advanced instrumentation. Integration with a major hospital system and statewide clinics enables patient access, clinical trials, and real‑world evidence collaborations. Minutes from Research Triangle Park, the university works within a dense corporate R&D ecosystem. Research is supported by strong competitive federal funding, including NIH and NSF, and a dedicated technology transfer office streamlines IP, licensing, MTAs, and startup formation.